Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Cholesterol-conjugated let-7amimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy

Figure 1

Chol-let-7a inhibited HCC cell growth and cell viability in vitro. A,B: MTT assays show the effects of Chol-let-7a and Chol-miRCtrl on the growth of HepG2 and SMMC7721 cells. The figure shows the growth curve of tumour cells from days 1–5. blank, parental cells; Chol-miRCtrl, Chol-miRCtrl-transfected cells; Chol-let-7a, Chol-let-7a-transfected cells. C: A chamber-based cell migration assay showing that Chol-let-7a inhibits the migration of HCC cells. HepG2: Chol-let-7a vs. Chol-miRCtrl vs. blank, 148.3 ± 7.02 vs. 203.0 ± 5.29 vs. 214.67 ± 11.67; T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.001; Chol-let-7a vs. blank, p = 0.005; Chol-miRCtrl vs. blank, p = 0.207. SMMC7721: Chol-let-7a vs. Chol-miRCtrl vs. blank, 155.67 ± 6.66 vs. 218.33 ± 9.45 vs.230.67 ± 7.02; T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.021; Chol-let-7a vs. blank, p = 0.01; Chol-miRCtrl vs. blank, p = 0.066. Magnification: 20× D: The inhibitory effect of Chol-let-7a on cell invasion ability in the Boyden chamber invasion assay. HepG2: Chol-let-7a vs. Chol-miRCtrl vs. blank, 66.33 ± 4.73vs. 91.33 ± 3.21 vs. 97.00 ± 5.29; T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.005; Chol-let-7a vs. blank, p = 0.026; Chol-miRCtrl vs. blank, p = 0.362. SMMC7721 cells: Chol-let-7a vs. Chol-miRCtrl vs. blank: 73.00 ± 5.29 vs. 91.33 ± 3.21 vs.103.33 ± 4.73. T-test: Chol-let-7a vs. Chol-miRCtrl, p = 0.019; Chol-let-7a vs. blank, p =0.016; Chol-miRCtrl vs. blank, p = 0.408. Magnification: 20×.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us